ARYD
NASDAQARYA Sciences Acquisition Corp IV
Website
News25/Ratings0
Latest news
25 items- PRAdagio Medical Provides Business UpdatesAdagio Medical Holdings, Inc. (NASDAQ:ADGM, the "Company"))), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today provided a business update. Recent Business Highlights: Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal Obtained the U.S. Food and Drug Administration ("FDA") approval for the FULCRUM-VT Pivotal IDE study Cl
- SECSEC Form 15-12G filed by ARYA Sciences Acquisition Corp IV15-12G - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
- INSIDERChief Executive Officer Stone Adam Leo returned 499,000 units of Class A ordinary shares to the company (SEC Form 4)4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)
- INSIDERSEC Form 4 filed by Director Henderson Michael Thomas4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)
- INSIDERSEC Form 4 filed by Director Trigg Leslie4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)
- INSIDERSEC Form 4 filed by Director Edelman Joseph4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)
- INSIDERSEC Form 4 filed by Chief Business Officer Poukalov Konstantin4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)
- INSIDERSEC Form 4 filed by Director Wider Todd4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)
- INSIDERLarge owner Arya Sciences Holdings Iv returned 499,000 units of Class A ordinary shares to the company (SEC Form 4)4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)
- INSIDERChief Financial Officer Altman Michael Seth returned 499,000 units of Class A ordinary shares to the company (SEC Form 4)4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)
- SECSEC Form 25-NSE filed by ARYA Sciences Acquisition Corp IV25-NSE - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)
- PRAdagio Medical Announces the Closing of the Business Combination with ARYA IV, Creating a Publicly Traded Company Focused on the Innovative Technologies for Treatment of Cardiac ArrhythmiasBusiness combination transaction with ARYA Sciences Acquisition Corp IV, a special purpose acquisition company sponsored by an affiliate of Perceptive Advisors, closed on July 31, 2024 Publicly traded company renamed Adagio Medical Holdings, Inc., with Adagio Medical as an operating subsidiary Common stock expected to commence trading under ticker symbol "ADGM" on the Nasdaq Capital Market on August 1, 2024 Adagio Medical, Inc. ("Adagio Medical"), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, announced today the completion of its business combination with ARYA Sciences Acquisition Corp IV (NASDAQ:ARYD, or "ARYA IV"))), a special purpos
- SECARYA Sciences Acquisition Corp IV filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
- SECARYA Sciences Acquisition Corp IV filed SEC Form 8-K: Other Events8-K - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
- SECSEC Form DEFM14A filed by ARYA Sciences Acquisition Corp IVDEFM14A - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
- SECARYA Sciences Acquisition Corp IV filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits8-K - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
- 13D/GAmendment: SEC Form SC 13G/A filed by ARYA Sciences Acquisition Corp IVSC 13G/A - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)
- SECARYA Sciences Acquisition Corp IV filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities8-K - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
- SECARYA Sciences Acquisition Corp IV filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
- SECARYA Sciences Acquisition Corp IV filed SEC Form 8-K: Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits8-K - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
- SECSEC Form 10-Q/A filed by ARYA Sciences Acquisition Corp IV (Amendment)10-Q/A - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
- SECSEC Form 10-Q filed by ARYA Sciences Acquisition Corp IV10-Q - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
- SECSEC Form NT 10-Q filed by ARYA Sciences Acquisition Corp IVNT 10-Q - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
- 13D/GSEC Form SC 13G/A filed by ARYA Sciences Acquisition Corp IV (Amendment)SC 13G/A - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)
- PRGenenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd WiderMILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and